ArticleThe Journal of physiology2026
METTL3-mediated m6A modification of circMtmr7 contributes to paclitaxel-induced peripheral neuropathy in the dorsal horn.
Article in The Journal of physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) lacks disease-modifying therapies, and how epitranscriptomic regulation drives central sensitization remains unclear. In the present study focusing on paclitaxel-induced peripheral neuropathy (PIPN), we identified a METTL3-circRNA axis in the spinal dorsal horn wherein upregulated METTL3 expanded the m6A-modified circMtmr7 pool in paclitaxel-treated mice. Accordingly in paclitaxel-treated mice, upregulated METTL3 paralleled elevated m6A-circMtmr7 expression; METTL3 knockdown prevented the paclitaxel-evoked rise in m6A-circMtmr7, normalized miniature excitatory postsynaptic current (EPSC) amplitude and frequency, as well as neuronal firing rates, and alleviated mechanical allodynia. Mechanistically circMtmr7 operated via two convergent branches to upregulate the effector NUFIP2: (i) in the cytoplasm it served as a microRNA (miRNA) sponge for miR-7010-5p, miR-3057-5p and miR-26b-3p, relieving repression and increasing NUFIP2; (ii) in the nucleus it associated with STAT5A to enhance NUFIP2 transcription, and silencing STAT5A reversed neuronal hyperexcitability and attenuated nociceptive behaviours. Genetic or pharmacological manipulation of METTL3, circMtmr7, STAT5A or NUFIP2 bidirectionally modulated neuronal excitability and nociceptive hypersensitivity. Collectively these data establish an m6A-dependent writer-circRNA-transcription factor hub that couples post-transcriptional and transcriptional programmes to amplify excitatory drive in PIPN, suggesting that STAT5A and NUFIP2 represent candidate targets for therapeutic development. KEY POINTS: In paclitaxel-treated mice, spinal dorsal horn METTL3 is upregulated, expanding the m6A-modified circMtmr7 pool to drive central sensitization in paclitaxel-induced peripheral neuropathy. circMtmr7 convergently upregulates NUFIP2 by acting as a cytoplasmic microRNA (miRNA) sponge and by associating with nuclear STAT5A to enhance transcription, thereby amplifying neuronal excitability. Pharmacological or genetic inhibition of METTL3, circMtmr7, STAT5A or NUFIP2 alleviates paclitaxel-induced nociceptive hypersensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.